Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04569747

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Sponsor: Dana-Farber Cancer Institute

Conditions Breast Cancer HER2-positive Breast Cancer Hormone Receptor Positive Breast Cancer Invasive Carcinoma of the Breast Micrometastasis Breast Cancer Node Negative Breast Cancer

Interventions ADJUVANT ENDOCRINE THERAPY Pertuzumab+TRASTUZUMAB

Updated 28 times since 2020 Last updated: Nov 12, 2025 Started: Jan 11, 2021 Primary completion: Sep 1, 2026 Completion: Sep 1, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and HER2-positive Breast Cancer and is currently actively recruiting participants. Dana-Farber Cancer Institute leads this study, which shows 28 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

28 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE2

▶ Show 23 earlier versions

Oct 2024 — Jul 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Dec 2023 — May 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Apr 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Apr 2022 — Jul 2022 [monthly]

Recruiting PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Sep 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Mar 2021 — May 2021 [monthly]

Recruiting PHASE2
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute
Genentech, Inc.

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Brewer, United States , Brooklyn, United States , Cary, United States , Chapel Hill, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Foxborough, United States and 13 more locations